Search

Your search keyword '"Överby AK"' showing total 53 results

Search Constraints

Start Over You searched for: Author "Överby AK" Remove constraint Author: "Överby AK"
53 results on '"Överby AK"'

Search Results

2. SARS-CoV-2 infection induces hyaluronan production in vitro and hyaluronan levels in COVID-19 patients relate to morbidity and long-term lung impairment: a prospective cohort study.

3. Transcriptional Response to Tick-Borne Flavivirus Infection in Neurons, Astrocytes and Microglia In Vivo and In Vitro.

4. An MR-based brain template and atlas for optical projection tomography and light sheet fluorescence microscopy in neuroscience.

5. The NSP3 protein of SARS-CoV-2 binds fragile X mental retardation proteins to disrupt UBAP2L interactions.

6. Identification of motif-based interactions between SARS-CoV-2 protein domains and human peptide ligands pinpoint antiviral targets.

7. Large-scale phage-based screening reveals extensive pan-viral mimicry of host short linear motifs.

8. Type I interferon shapes brain distribution and tropism of tick-borne flavivirus.

9. At-home sampling to meet geographical challenges for serological assessment of SARS-CoV-2 exposure in a rural region of northern Sweden, March to May 2021: a retrospective cohort study.

10. Simultaneous membrane and RNA binding by tick-borne encephalitis virus capsid protein.

11. A Syntenin Inhibitor Blocks Endosomal Entry of SARS-CoV-2 and a Panel of RNA Viruses.

12. Serine Protease Inhibitors Restrict Host Susceptibility to SARS-CoV-2 Infections.

13. Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients.

14. Serological assessment of SARS-CoV-2 exposure in northern Sweden by the use of at-home sampling to meet geographical challenges in rural regions.

15. Re: Chen Dong, Sung-Lang Chen, and Wen-Wei Sung's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-93.

16. Molecular Organisation of Tick-Borne Encephalitis Virus.

17. Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases.

18. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data.

19. Fluvastatin mitigates SARS-CoV-2 infection in human lung cells.

20. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden.

21. Large scale discovery of coronavirus-host factor protein interaction motifs reveals SARS-CoV-2 specific mechanisms and vulnerabilities.

22. BAF45b Is Required for Efficient Zika Virus Infection of HAP1 Cells.

23. COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial.

24. PKR kinase directly regulates tau expression and Alzheimer's disease-related tau phosphorylation.

25. The envelope protein of tick-borne encephalitis virus influences neuron entry, pathogenicity, and vaccine protection.

26. N -glycosylation in the Pre-Membrane Protein Is Essential for the Zika Virus Life Cycle.

27. Revealing new tick-borne encephalitis virus foci by screening antibodies in sheep milk.

28. Antiviral Activity of Benzavir-2 against Emerging Flaviviruses.

29. Quantitative Proteomics of Uukuniemi Virus-host Cell Interactions Reveals GBF1 as Proviral Host Factor for Phleboviruses.

30. Model System for the Formation of Tick-Borne Encephalitis Virus Replication Compartments without Viral RNA Replication.

31. Characterizing the cellular attachment receptor for Langat virus.

32. Tick-borne encephalitis in Europe and Russia: Review of pathogenesis, clinical features, therapy, and vaccines.

33. Competitive repopulation of an empty microglial niche yields functionally distinct subsets of microglia-like cells.

34. The Role of Viperin in Antiflavivirus Responses.

35. Correlation of Severity of Human Tick-Borne Encephalitis Virus Disease and Pathogenicity in Mice.

36. Tick-Borne Flaviviruses and the Type I Interferon Response.

38. Cell-type- and region-specific restriction of neurotropic flavivirus infection by viperin.

39. Viperin Restricts Zika Virus and Tick-Borne Encephalitis Virus Replication by Targeting NS3 for Proteasomal Degradation.

40. The interplay between viperin antiviral activity, lipid droplets and Junín mammarenavirus multiplication.

41. Viperin Targets Flavivirus Virulence by Inducing Assembly of Noninfectious Capsid Particles.

42. Cellular requirements for iron-sulfur cluster insertion into the antiviral radical SAM protein viperin.

43. The role of the poly(A) tract in the replication and virulence of tick-borne encephalitis virus.

44. Fast type I interferon response protects astrocytes from flavivirus infection and virus-induced cytopathic effects.

45. Brain heterogeneity leads to differential innate immune responses and modulates pathogenesis of viral infections.

46. Human Tick-Borne Encephalitis and Characterization of Virus from Biting Tick.

47. High-Throughput Screening Using a Whole-Cell Virus Replication Reporter Gene Assay to Identify Inhibitory Compounds against Rift Valley Fever Virus Infection.

48. Type I Interferon response in olfactory bulb, the site of tick-borne flavivirus accumulation, is primarily regulated by IPS-1.

49. Generation of mutant Uukuniemi viruses lacking the nonstructural protein NSs by reverse genetics indicates that NSs is a weak interferon antagonist.

50. Type I interferon protects mice from fatal neurotropic infection with Langat virus by systemic and local antiviral responses.

Catalog

Books, media, physical & digital resources